IL130171A - Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines - Google Patents
Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicinesInfo
- Publication number
- IL130171A IL130171A IL13017199A IL13017199A IL130171A IL 130171 A IL130171 A IL 130171A IL 13017199 A IL13017199 A IL 13017199A IL 13017199 A IL13017199 A IL 13017199A IL 130171 A IL130171 A IL 130171A
- Authority
- IL
- Israel
- Prior art keywords
- melatonin
- neuroleptic
- treatment
- pharmaceutical formulation
- compound
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 43
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960003987 melatonin Drugs 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 206010043118 Tardive Dyskinesia Diseases 0.000 title claims abstract description 15
- 230000002265 prevention Effects 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 239000003814 drug Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 230000000701 neuroleptic effect Effects 0.000 claims description 17
- 239000003176 neuroleptic agent Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229960003878 haloperidol Drugs 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- 229960000762 perphenazine Drugs 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001076 chlorpromazine Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 claims description 4
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 claims description 4
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 claims description 4
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims description 4
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims description 4
- 229960001552 chlorprothixene Drugs 0.000 claims description 4
- 229960003864 clotiapine Drugs 0.000 claims description 4
- 229960004170 clozapine Drugs 0.000 claims description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002690 fluphenazine Drugs 0.000 claims description 4
- 229960004938 molindone Drugs 0.000 claims description 4
- 229960005017 olanzapine Drugs 0.000 claims description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004265 piperacetazine Drugs 0.000 claims description 4
- 229960001534 risperidone Drugs 0.000 claims description 4
- 229960002784 thioridazine Drugs 0.000 claims description 4
- 229960005013 tiotixene Drugs 0.000 claims description 4
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002324 trifluoperazine Drugs 0.000 claims description 4
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003904 triflupromazine Drugs 0.000 claims description 4
- OXAUOBQMCDIVPQ-IOXNKQMXSA-N zuclopenthixol acetate Chemical compound C1CN(CCOC(=O)C)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 OXAUOBQMCDIVPQ-IOXNKQMXSA-N 0.000 claims description 4
- 229960003939 zuclopenthixol acetate Drugs 0.000 claims description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 3
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 claims description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 3
- 102000001419 Melatonin receptor Human genes 0.000 claims description 3
- 108050009605 Melatonin receptor Proteins 0.000 claims description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
- 229960000276 acetophenazine Drugs 0.000 claims description 3
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229960000423 loxapine Drugs 0.000 claims description 3
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960000300 mesoridazine Drugs 0.000 claims description 3
- 229950000688 phenothiazine Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 2
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000012661 Dyskinesia Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- -1 Compounds Compound Chemical class 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229960004035 acetophenazine maleate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000589 loxapine succinate Drugs 0.000 description 1
- 229960003664 mesoridazine besylate Drugs 0.000 description 1
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Priority Applications (31)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13017199A IL130171A (en) | 1999-05-27 | 1999-05-27 | Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines |
TR2001/03418T TR200103418T2 (tr) | 1999-05-27 | 2000-05-24 | Melatoninin tedavi edici kullanımı. |
JP2000620955A JP2003500446A (ja) | 1999-05-27 | 2000-05-24 | メラトニンの治療的使用法 |
EP00929756A EP1183024A4 (en) | 1999-05-27 | 2000-05-24 | THERAPEUTIC USE OF MELATONIN |
UA2001128828A UA71968C2 (en) | 1999-05-27 | 2000-05-24 | Melatonin-containing pharmaceutic composition (variants) and method for preventing and treating tardive dyskinesia |
CZ20014190A CZ20014190A3 (cs) | 1999-05-27 | 2000-05-24 | Terapeutické pouľití melatoninu |
MXPA01012040A MXPA01012040A (es) | 1999-05-27 | 2000-05-24 | Uso terapeutico de la melatonina. |
SK1640-2001A SK16402001A3 (sk) | 1999-05-27 | 2000-05-24 | Terapeutické použitie melatonínu |
US09/979,583 US6566389B1 (en) | 1999-05-27 | 2000-05-24 | Therapeutic uses of melatonin |
PCT/IL2000/000296 WO2000072843A1 (en) | 1999-05-27 | 2000-05-24 | Therapeutic use of melatonin |
CNB008081069A CN1176652C (zh) | 1999-05-27 | 2000-05-24 | 褪黑激素在治疗疾病方面的应用 |
CA002374129A CA2374129A1 (en) | 1999-05-27 | 2000-05-24 | Therapeutic use of melatonin |
NZ515866A NZ515866A (en) | 1999-05-27 | 2000-05-24 | Therapeutic use of melatonin |
KR1020017014958A KR20020015329A (ko) | 1999-05-27 | 2000-05-24 | 멜라토닌의 치료학적 용도 |
AU47756/00A AU775520B2 (en) | 1999-05-27 | 2000-05-24 | Therapeutic use of melatonin |
HU0201405A HUP0201405A3 (en) | 1999-05-27 | 2000-05-24 | Pharmaceutical composition for therapeutic use of melatonin |
BR0017329-0A BR0017329A (pt) | 1999-05-27 | 2000-05-24 | Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento |
EA200101240A EA004057B1 (ru) | 1999-05-27 | 2000-05-24 | Использование мелатонина в медицине |
PL00351885A PL351885A1 (en) | 1999-05-27 | 2000-05-24 | Therapeutic applications of melatonin |
EEP200100623A EE200100623A (et) | 1999-05-27 | 2000-05-24 | Melatoniini terapeutiline kasutamine |
PE2000000503A PE20010129A1 (es) | 1999-05-27 | 2000-05-26 | Composicion que comprende un neuroleptico y melatonina |
TNTNSN00117A TNSN00117A1 (fr) | 1999-05-27 | 2000-05-26 | Neurim pharmaceuticals eec ltd |
UY26171A UY26171A1 (es) | 1999-05-27 | 2000-05-26 | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía |
ARP000102569A AR036321A1 (es) | 1999-05-27 | 2000-05-26 | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. |
TW089110619A TWI236906B (en) | 1999-05-27 | 2000-05-31 | Therapeutic use of melatonin |
IS6172A IS6172A (is) | 1999-05-27 | 2001-11-22 | Notkun melatoníns til lækninga |
NO20015738A NO319421B1 (no) | 1999-05-27 | 2001-11-26 | Terapeutisk bruk av melatonin |
BG106234A BG106234A (bg) | 1999-05-27 | 2001-12-18 | Терапевтична употреба на мелатонин |
ZA200110436A ZA200110436B (en) | 1999-05-27 | 2001-12-20 | Therapeutic use of melatonin. |
HK02106585.6A HK1046089A1 (zh) | 1999-05-27 | 2002-09-06 | 褪黑激素的治療用途 |
HK02108721.7A HK1047048B (zh) | 1999-05-27 | 2002-11-29 | 褪黑激素在治療疾病方面的應用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13017199A IL130171A (en) | 1999-05-27 | 1999-05-27 | Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines |
Publications (2)
Publication Number | Publication Date |
---|---|
IL130171A0 IL130171A0 (en) | 2000-06-01 |
IL130171A true IL130171A (en) | 2004-06-01 |
Family
ID=11072852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13017199A IL130171A (en) | 1999-05-27 | 1999-05-27 | Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines |
Country Status (30)
Country | Link |
---|---|
US (1) | US6566389B1 (es) |
EP (1) | EP1183024A4 (es) |
JP (1) | JP2003500446A (es) |
KR (1) | KR20020015329A (es) |
CN (1) | CN1176652C (es) |
AR (1) | AR036321A1 (es) |
AU (1) | AU775520B2 (es) |
BG (1) | BG106234A (es) |
BR (1) | BR0017329A (es) |
CA (1) | CA2374129A1 (es) |
CZ (1) | CZ20014190A3 (es) |
EA (1) | EA004057B1 (es) |
EE (1) | EE200100623A (es) |
HK (2) | HK1046089A1 (es) |
HU (1) | HUP0201405A3 (es) |
IL (1) | IL130171A (es) |
IS (1) | IS6172A (es) |
MX (1) | MXPA01012040A (es) |
NO (1) | NO319421B1 (es) |
NZ (1) | NZ515866A (es) |
PE (1) | PE20010129A1 (es) |
PL (1) | PL351885A1 (es) |
SK (1) | SK16402001A3 (es) |
TN (1) | TNSN00117A1 (es) |
TR (1) | TR200103418T2 (es) |
TW (1) | TWI236906B (es) |
UA (1) | UA71968C2 (es) |
UY (1) | UY26171A1 (es) |
WO (1) | WO2000072843A1 (es) |
ZA (1) | ZA200110436B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7799817B2 (en) * | 2004-02-20 | 2010-09-21 | Lifescape Biosciences Inc | Compositions and methods for sleep regulation |
CN1299680C (zh) * | 2005-08-29 | 2007-02-14 | 陈彦方 | 一种治疗失眠的黑白制剂 |
US7494674B2 (en) | 2006-09-22 | 2009-02-24 | Lapointe Andrew T | Nutraceutical with tart cherries and method of treatment therewith |
EP2124907B1 (en) | 2007-03-19 | 2018-05-30 | Vita Sciences, Llc | Transdermal patch and method for delivery of vitamin b12 |
WO2008128166A1 (en) * | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
US20100256215A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Menthol-Melatonin Dissolving Film |
US20100256197A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Nicotine Dissolving Film With Or Without Menthol |
WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
FR3000896B1 (fr) | 2013-01-14 | 2016-08-26 | Philippe Perovitch | Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil |
US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691324A (en) * | 1994-01-14 | 1997-11-25 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
US6469044B1 (en) * | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
AUPO274596A0 (en) * | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
AUPO588297A0 (en) * | 1997-03-26 | 1997-04-24 | Luminis Pty Limited | Mediation in melatonin production |
-
1999
- 1999-05-27 IL IL13017199A patent/IL130171A/en not_active IP Right Cessation
-
2000
- 2000-05-24 EP EP00929756A patent/EP1183024A4/en not_active Withdrawn
- 2000-05-24 KR KR1020017014958A patent/KR20020015329A/ko not_active Application Discontinuation
- 2000-05-24 PL PL00351885A patent/PL351885A1/xx not_active Application Discontinuation
- 2000-05-24 BR BR0017329-0A patent/BR0017329A/pt not_active IP Right Cessation
- 2000-05-24 EA EA200101240A patent/EA004057B1/ru not_active IP Right Cessation
- 2000-05-24 CZ CZ20014190A patent/CZ20014190A3/cs unknown
- 2000-05-24 US US09/979,583 patent/US6566389B1/en not_active Expired - Lifetime
- 2000-05-24 SK SK1640-2001A patent/SK16402001A3/sk unknown
- 2000-05-24 HU HU0201405A patent/HUP0201405A3/hu unknown
- 2000-05-24 TR TR2001/03418T patent/TR200103418T2/xx unknown
- 2000-05-24 CA CA002374129A patent/CA2374129A1/en not_active Abandoned
- 2000-05-24 AU AU47756/00A patent/AU775520B2/en not_active Ceased
- 2000-05-24 NZ NZ515866A patent/NZ515866A/en unknown
- 2000-05-24 UA UA2001128828A patent/UA71968C2/uk unknown
- 2000-05-24 MX MXPA01012040A patent/MXPA01012040A/es not_active Application Discontinuation
- 2000-05-24 CN CNB008081069A patent/CN1176652C/zh not_active Expired - Fee Related
- 2000-05-24 WO PCT/IL2000/000296 patent/WO2000072843A1/en not_active Application Discontinuation
- 2000-05-24 JP JP2000620955A patent/JP2003500446A/ja active Pending
- 2000-05-24 EE EEP200100623A patent/EE200100623A/xx unknown
- 2000-05-26 PE PE2000000503A patent/PE20010129A1/es not_active Application Discontinuation
- 2000-05-26 AR ARP000102569A patent/AR036321A1/es not_active Application Discontinuation
- 2000-05-26 UY UY26171A patent/UY26171A1/es unknown
- 2000-05-26 TN TNTNSN00117A patent/TNSN00117A1/fr unknown
- 2000-05-31 TW TW089110619A patent/TWI236906B/zh not_active IP Right Cessation
-
2001
- 2001-11-22 IS IS6172A patent/IS6172A/is unknown
- 2001-11-26 NO NO20015738A patent/NO319421B1/no unknown
- 2001-12-18 BG BG106234A patent/BG106234A/bg unknown
- 2001-12-20 ZA ZA200110436A patent/ZA200110436B/xx unknown
-
2002
- 2002-09-06 HK HK02106585.6A patent/HK1046089A1/zh unknown
- 2002-11-29 HK HK02108721.7A patent/HK1047048B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1077501A1 (en) | Improved delivery of multiple doses of a methylphenidate drug | |
NZ508526A (en) | Opioid formulations for treating pain | |
AU775520B2 (en) | Therapeutic use of melatonin | |
EP1258245A2 (en) | Accelerated release composition containing bromocriptine | |
GR3036798T3 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
EP1227798A4 (en) | HYDRCODON FORMULATIONS WITH CONTROLLED RELEASE | |
TW228474B (es) | ||
US3978216A (en) | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs | |
MXPA05009850A (es) | Metodo para tratar el deterioro cognitivo leve y para prevenir o atrasar la enfermedad de alzheimer. | |
US4138484A (en) | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs | |
Mystakidou et al. | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics | |
US4084000A (en) | Method of treating schizophrenia | |
US4129652A (en) | Method for potentiating neuroleptic drugs | |
Martin et al. | Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats | |
NZ315632A (en) | Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water | |
KR20080054394A (ko) | 프랄나카산의 지연 방출 제형 | |
CA2396351A1 (en) | New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | |
CA2187153A1 (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |